Genflow Biosciences

GENF · Main Market · Health Care · mcap £12m · 1.8p

Beta Briefing, track record and bull & bear case are not ready for Genflow Biosciences yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 54 companies are already wired into a briefing: browse them.

All announcements Monitoring checked today, 17:05

All · 36 Key · 29

Date	Type	Announcement	Day
09 Oct 26		Corporate Update Japanese Patent Allowance and Expanded Animal Health Interest in SIRT6 Gene Therapy	−2.2%
05 Oct 26	Results	Presentation of Interim Results Presentation of Interim Results from SLAB Canine Study at the Animal Longevity Summit	−13.3%
29 Sep 26		Exercise of Warrants and Issue of Equity Genflow (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a biotechnology company focused on the development of gene therapies for age-related diseases announces that it has received notices of exercise of warrant	+0.0%
29 Sep 26	Results	Half-year Results Genflow (LSE: GENF) (OTCQB:GENFF) is pleased to announce its half year results for the six-month period ended 30 June 2022.	+0.0%
08 Sep 26		Primary Endpoint in SLAB Clinical Trial Met Genflow Meets Primary Endpoint in SLAB Clinical Trial	−2.4%
07 Sep 26		Appointment of Investor Relations Adviser Genflow Appoints ON365 Partners as Investor Relations Adviser	+13.1%
03 Aug 26		Patent Update Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or the "Company"), an emerging leader in the field of longevity research, announces progress across its two principal SIRT6 patent families covering its centena	+16.4%
13 Jul 26		Mid-Year Operational and Corporate Summary Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or the "Company"), an emerging leader in the field of longevity research, provides a mid-year operational and corporate summary covering the six-month period to	−1.3%
29 Jun 26	Routine	Result of AGM
22 Jun 26		Participation at BIO International Convention 2026 Genflow Announces Participation at BIO International Convention 2026	+3.7%
17 Jun 26		Company to present at Animal Longevity Summit 2026 Genflow Biosciences to Present SLAB Trial Results at Animal Longevity Summit 2026	−1.2%
04 Jun 26	Routine	Notice of AGM
08 May 26		Exercise of Warrants and Issue of Equity Genflow (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a biotechnology company focused on the development of gene therapies for age-related diseases announces that it has received notices of exercise of warrant	−7.7%
30 Apr 26	Results	Final Results Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases	−1.1%
28 Apr 26		Expansion of Confidentiality Agreements Expansion of Confidentiality Agreements with Tier-1 Animal Health Companies	+12.0%
20 Apr 26		Strategic Technology Collaboration Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas Therapeutics - Fully Funded, Non-Dilutive Access to World-Class LNP Delivery Platform	+16.9%
13 Apr 26		International Patent Publication International Patent Publication Expands Protection for SIRT6-Based Muscular Disease Program	+10.3%
08 Apr 26		Update on the Dog Study Genflow Reports Sustained Safety and Efficacy Three Months Post Dosing in SLAB Trial	−9.1%
31 Mar 26	Routine	Total Voting Rights
05 Mar 26	Director dealing	Issue of Equity & PDMR Notifications
02 Mar 26		Result of General Meeting Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company focusing on longevity, is pleased to announce that all resolutions proposed at the General Meet	−5.0%
02 Mar 26		Receipt of First Tranche of Grant Receipt of First Tranche of €4 Million Non-Dilutive Funding from Wallonia Region for GF-1002 Development	−5.0%
12 Feb 26	Results	Preliminary Interim Results From Dog Study Positive Preliminary Interim Results from SLAB Clinical Trial of SIRT6 Gene Therapy in Aged Dogs	+0.0%
11 Feb 26		Notice of GM Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces that the Board is c	−9.5%
30 Jan 26	Holding	Holding(s) in Company
28 Jan 26		Administrative Approval of Grant & 2026 Priorities Administrative Approval of €4 Million Funding Support from Wallonia Region for GF-100; and 2026 Development Priorities	−2.6%
19 Jan 26	Board change	Directorate Change Genflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion	+5.4%
08 Jan 26		Review of 2025 2025 has been a year of focused scientific progress and continued advancement of Genflow Bioscience's mission to extend healthy lifespan through our novel longevity gene therapy platform.	+0.0%
16 Dec 25		Completion of Dosing Phase of Canine Gene Therapy Genflow Completes Dosing Phase of Canine Gene Therapy Trial	+1.4%
11 Dec 25		Genflow to Attend Healthcare Conference Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), a leading European-based biotechnology company focusing on longevity, announces that it will attend the 44th Annual J.P.	−11.5%
31 Oct 25	Routine	Total Voting Rights
24 Oct 25	Holding	Holding(s) in Company
22 Oct 25		Second European Patent Application Publication of Second European Patent Application - SIRT6 Variant for NASH	−0.9%
20 Oct 25		Recognition of Patentability of Claims European Patent Office 2025 Recognizes the Patentability of Claims of SIRT 6 Variant Patent	−4.4%
10 Oct 25		Update on Animal Health Program LONDON, UK-Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to provide an update on its Dog Aging (GF-1004) study, a proof-of-	+1.9%
09 Oct 25	Director dealing	Update, Equity Issue and PDMR Notification Termination of Initial Transaction, Subscription of New Ordinary Shares, Warrant Issue and PDMR Dealings	+90.9%

Company filings. Not investment advice.